Developing a new treatment for triple-negative breast cancer
Official title: Developing LG007 as a novel therapeutic agent to treat triple negative breast cancer
Funded at University of Georgia · NIH-10928807 · Data updated 2026-11-12
This study is looking at a new treatment called LG007 to see how well it works against a tough type of breast cancer called triple-negative breast cancer, using special mice that have tumors from real patients, to help find better options for people fighting this disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $1 |
| NIH project number | 5R01CA260698-04 |
| Project ID | NIH-10928807 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with triple-negative breast cancer, particularly those who have not responded well to existing treatments.
✕Less likely to help
Patients with other subtypes of breast cancer or those who are not diagnosed with breast cancer may not benefit from this research.
What this research studies
This research focuses on a specific and aggressive subtype of breast cancer known as triple-negative breast cancer (TNBC), which is challenging to treat with standard therapies. The study aims to investigate a novel compound called LG007 for its effectiveness against TNBC using patient-derived xenograft (PDX) mouse models. By examining how LG007 impacts tumor growth and metastasis in these models, the research seeks to provide insights into a potentially more effective treatment option for patients suffering from this disease.
Why it matters
Potential benefit: If successful, this research could lead to a new therapeutic option that significantly improves outcomes for patients with triple-negative breast cancer.
How similar studies have gone: Preliminary results from similar research have shown promise, indicating that LG007 could be a potent drug candidate for treating progressive TNBC.
Where this research is happening
-
University of Georgia
Athens, United States Active
Researchers
- Principal investigator: Xi, Yaguang — University of Georgia
- Study coordinator: Xi, Yaguang
Related research
Other NIH-funded projects on the same topics.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Linking heavy metal exposure to a tougher breast cancer type (TNBC)
Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.
-
Dormancy in Triple-Negative Breast Cancer: How Liver and Skin Metastases Go Quiet or Reactivate
Researchers will study how dormant cancer cells in liver and skin metastases of triple-negative breast cancer become quiescent or wake up, using organ-on-chip models and single-cell analysis to map chromatin states.
-
Rac-enhanced CAR-Macrophages against TNBC
A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.
-
A new peptide therapy to help treat metastatic triple-negative breast cancer
A new peptide therapy called PEG-FUD is being tested to help treat metastatic triple-negative breast cancer by normalizing the tumor environment to improve treatment delivery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.